MX2020010199A - Polipeptidos antigenicos del virus sincitial respiratorio. - Google Patents

Polipeptidos antigenicos del virus sincitial respiratorio.

Info

Publication number
MX2020010199A
MX2020010199A MX2020010199A MX2020010199A MX2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A
Authority
MX
Mexico
Prior art keywords
respiratory syncytial
syncytial virus
antigenic
virus polypeptides
polypeptides
Prior art date
Application number
MX2020010199A
Other languages
English (en)
Spanish (es)
Inventor
Kurt Swanson
Pradeep Dhal
Magnus Besev
Gary J Nabel
Chih- Jen Wei
Ram Dharanipragada
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2020010199A publication Critical patent/MX2020010199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2020010199A 2018-04-03 2019-04-02 Polipeptidos antigenicos del virus sincitial respiratorio. MX2020010199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652199P 2018-04-03 2018-04-03
PCT/US2019/025387 WO2019195291A1 (en) 2018-04-03 2019-04-02 Antigenic respiratory syncytial virus polypeptides

Publications (1)

Publication Number Publication Date
MX2020010199A true MX2020010199A (es) 2021-01-08

Family

ID=66182672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010199A MX2020010199A (es) 2018-04-03 2019-04-02 Polipeptidos antigenicos del virus sincitial respiratorio.

Country Status (10)

Country Link
US (2) US12071454B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773704A1 (cg-RX-API-DMAC7.html)
JP (2) JP7614841B2 (cg-RX-API-DMAC7.html)
KR (1) KR102964264B1 (cg-RX-API-DMAC7.html)
CN (1) CN112512567A (cg-RX-API-DMAC7.html)
AU (1) AU2019247034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019938A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020010199A (cg-RX-API-DMAC7.html)
WO (1) WO2019195291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023201222A1 (en) * 2022-04-11 2023-10-19 Vanderbilt University Ferritin nanoparticles and methods of use thereof
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
KR20250099727A (ko) 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
US20250009865A1 (en) 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
CN122180699A (zh) * 2023-08-03 2026-06-09 广州宾和企业管理合伙企业(有限合伙) 修饰的呼吸道合胞病毒f蛋白及其用途
WO2025092933A1 (zh) * 2023-10-31 2025-05-08 上海蓝鹊生物医药有限公司 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽
CN120099235A (zh) * 2025-05-09 2025-06-06 北京华诺泰生物医药科技有限公司 一种微生物发酵工艺的优化方法及装置

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407182A (pt) 1993-08-06 1996-09-17 Connaught Lab Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20100285051A1 (en) 2007-12-21 2010-11-11 Dominique Ingrid Lemoine Vaccine
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
US20110117131A1 (en) 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
US20140186371A1 (en) 2011-04-07 2014-07-03 Guriqbal S. Basi Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
JP5795184B2 (ja) 2011-04-22 2015-10-14 国立大学法人 奈良先端科学技術大学院大学 被検物質の電気化学的検出方法
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
EP2758075B1 (en) * 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
EP2877205A4 (en) 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
US10363301B2 (en) * 2014-05-27 2019-07-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
US10301377B2 (en) * 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN109310749B (zh) 2016-06-07 2022-09-23 德国癌症研究中心 Hpv l2肽免疫原性的改善
KR102724939B1 (ko) 2016-06-17 2024-11-01 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
MA50813A (fr) 2017-11-21 2020-09-30 Modernatx Inc Vaccins contre le virus d'epstein-barr
CN112584858A (zh) 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイSanofi 抗原性インフルエンザ−フェリチンポリペプチド
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド

Also Published As

Publication number Publication date
WO2019195291A1 (en) 2019-10-10
JP2021519597A (ja) 2021-08-12
RU2020135568A (ru) 2022-05-06
CA3095175A1 (en) 2019-10-10
JP7614841B2 (ja) 2025-01-16
US12071454B2 (en) 2024-08-27
BR112020019938A2 (pt) 2021-01-26
KR102964264B1 (ko) 2026-05-13
US20250059240A1 (en) 2025-02-20
AU2019247034A1 (en) 2020-10-22
US20210017237A1 (en) 2021-01-21
KR20210018206A (ko) 2021-02-17
JP2024170566A (ja) 2024-12-10
EP3773704A1 (en) 2021-02-17
CN112512567A (zh) 2021-03-16
AU2019247034B2 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
WO2019195314A3 (en) Antigenic epstein barr virus polypeptides
MX2025009589A (es) Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
PH12018501882A1 (en) Binding proteins and methods of use thereof
IL260218A (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
WO2018187356A3 (en) Protein antigens and uses thereof
EP4223784A3 (en) Compositions and methods for modulating t-cell mediated immune response
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
EA202190136A1 (ru) Способ очистки антигена
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
MX2019011952A (es) Proteina anti-garp y sus usos.
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MX385818B (es) Proteínas f de rsv de prefusión y su uso.
ZA202101260B (en) Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof
WO2013150309A8 (en) Clostridium difficile antigens
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
SG11202101973YA (en) Pneumococcal fusion protein vaccines
WO2017040329A3 (en) Peptides binding to bfl-1
EP3778634A4 (en) GCGR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
HK1243329A1 (zh) 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途